Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Augusta Eduafo, DO, Leland Metheny, III, MD, James Driscoll, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139856

Published: 2020

Journal Articles

Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Shivaprasad Manjappa, MDMBBS, Robert Fox, Jane Reese, Amin Firoozamand, MD, Hannah Schmikla, RN, Savannah Nall, RN, Merle Kolk, Paolo F Caimi, MD, James J. Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142115

Published: 2020

Journal Articles

Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Ehsan Malek, MD, E. Ricky Chan, PhD, Daniel Qu, Jane Reese, Robert Fox, Byung-Gyu Kim, PhD DVM, Paolo F Caimi, MD, Marcos de Lima, MD, James J. Driscoll, MD PhD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142791

Published: 2020

Journal Articles

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBBChir,MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Gisele Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny, III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, EDuardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlak, MD PhD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142197

Published: 2020

Journal Articles

Health Care Burden of Monogammopathy of Renal Significance

Jeries Kort, MD, Paolo F Caimi, MD, Pingfu Fu, PhD, Shufen Cao, James Driscoll, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 34–36.

https://doi.org/10.1182/blood-2020-139740

Published: 2020

Journal Articles

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Anna Eversman, Shufen Cao, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, III, MD, Timothy E. O'Brien, MD, Folashade Otegbeye, MBBChir,MPH, Brenda W. Cooper, MD, Pingfu Fu, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140042

Published: 2020

Journal Articles

Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma

Augustine Hong, MD, Augusta Eduafo, DO, Hannah Schmikla, RN, George Brown, Gayathri Ravi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-140544

Published: 2020

Journal Articles

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Ehsan Malek, MD, Jeries Kort, MD, Gi-Ming Wang, PhD, Paolo F Caimi, MD, Kirsten M Boughan, DO, Stanton L. Gerson, MD, Brenda W. Cooper, MD, Molly M Gallogly, MDPhD, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Curtis Tatsuoka, PhD, James Driscoll

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-139733

Published: 2020

Journal Articles

Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs

Amin Firoozmand, MD, Naveed Ali, MD, Nausheen Ahmed, MD, Pingfu Fu, Shufen Cao, George Brown, Hannah Schmikla, RN, James J. Driscoll, MD PhD, Timothy O'Brien, Paolo Caimi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140800

Published: 2020

Journal Articles

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Ehsan Malek, MD, Petra Martin, Paolo F Caimi, MD, Benjamin K. Tomlinson, MD, Michael Caldwell, Gayathri Ravi, MD, Sowjanya Vuyyala, MD, Hannah Schmikla, RN, Robert Fox, Marcos de Lima, MD, Navid Sadri, MD, James Driscoll, MD PhD

Blood (2019) 134 (Supplement_1): 515.

https://doi.org/10.1182/blood-2019-127335

Published: 2019

Journal Articles

Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients

Gayathri Ravi, MD, Kamal Chamoun, MD, Kirsten M Boughan, DO, Shufen Cao, Pingfu Fu, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 424.

https://doi.org/10.1182/blood-2019-126131

Published: 2019

Journal Articles

Risk of Progression in Patients with Smoldering Myeloma

Fahrettin Covut, MD, Kamal Chamoun, MD, Leland Metheny, III, MD, Kirsten M Boughan, DO, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 1892.

https://doi.org/10.1182/blood-2019-127677

Published: 2019

Journal Articles

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Leland Metheny, III, MD, Ronald Sobecks, MD, Benjamin K. Tomlinson, MD, Folashade Otegbeye, MBBChir,MPH, Brenda Cooper, MD, Navneet S. Majhail, MD MS, Paolo Caimi, MD, Kirsten M Boughan, DO, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Erin Galloway, RN BSN, Betty K. Hamilton, MD, Matt Kalaycio, MD, Aaron T. Gerds, MD MS, Marcos de Lima, MD

Blood (2019) 134 (Supplement_1): 1948.

https://doi.org/10.1182/blood-2019-125940

Published: 2019

Journal Articles

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Fahrettin Covut, MD, Tariq Zuheir Kewan, MD, Apoorva Anandan, MD, Folashade Otegbeye, MBBChir,MPH, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 2196.

https://doi.org/10.1182/blood-2019-125954

Published: 2019

Journal Articles

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Jiasheng Wang, MD, Kirsten M Boughan, DO, Paolo F Caimi, MD, Brenda Cooper, MD, Marcos de Lima, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Shufen Cao, Pingfu Fu, PhD, Benjamin Tomlinson, MD

Blood (2019) 134 (Supplement_1): 2607.

https://doi.org/10.1182/blood-2019-131293

Published: 2019

Journal Articles

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Shufen Cao, Gouri Dharmavaram, Kirsten M Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Pingfu Fu, Paolo F Caimi, MD

Blood (2019) 134 (Supplement_1): 4770.

https://doi.org/10.1182/blood-2019-131527

Published: 2019

Journal Articles

The Prognostic Factors for Early Fatal Outcome in Patients with Multiple Myeloma

Sowjanya Vuyyala, MD, Kamal Chamoun, MD, Pingfu Fu, Shufen Cao, Molly M Gallogly, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 270.

https://doi.org/10.1182/blood-2019-126156

Published: 2019

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Blood (2019) 134 (Supplement_1): 3125.

https://doi.org/10.1182/blood-2019-124991

Published: 2019

Journal Articles

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Apoorva Anandan, MD, Pingfu Fu, Merle Kolk, Nicole Ferrari, Arash Rashidi, MD, Melissa Copley, PharmD, James Driscoll, MD PhD, Paolo Caimi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 5646.

https://doi.org/10.1182/blood-2019-122057

Published: 2019

NARROW

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Health Care Burden of Monogammopathy of Renal Significance

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients

Risk of Progression in Patients with Smoldering Myeloma

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

The Prognostic Factors for Early Fatal Outcome in Patients with Multiple Myeloma

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only